TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01874028
Drug: trientine dihydrochloride
Normalized name: trientine dihydrochloride 300 MG Oral Capsule
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
Study: NCT02339168
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02339168
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02066844
Drug: Celestone
Normalized name: Celestone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2cc
Study: NCT02066844
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5cc
Study: NCT02101944
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02101944
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03036826
Drug: Piperacillin/tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiinfective therapy with Piperacillin/Tazobactam within routine care
Study: NCT03036826
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antiinfective therapy with Meropenem within routine care
Study: NCT04499989
Drug: INH
Normalized name: INH
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
Study: NCT01753167
Drug: MCMV5322A
Normalized name: MCMV5322A
DrugBank: MCMV5322A (DB17763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Study: NCT01900743
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
Study: NCT00861471
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days.
Study: NCT00861471
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.
Study: NCT02157077
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection
Study: NCT01007721
Drug: BI 67100 ED 25 mg
Normalized name: Ed-APAP
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of BI 671800 ED 25 mg
Study: NCT01007721
Drug: BI 671800 ED placebo
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)
Study: NCT01007721
Drug: montelukast placebo tablet
Normalized name: placebo Oral Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Study: NCT00968877
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule 40 000 IU (p.o.) once per week, in 8 weeks.
Study: NCT02997982
Drug: Valaciclovir 500Mg Tablet
Normalized name: valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
Study: NCT02419820
Drug: APD791
Normalized name: APD791
DrugBank: APD791 (DB05227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temanogrel
Study: NCT02419820
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel
Study: NCT02419820
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin
Study: NCT02419820
Drug: Placebo for APD791
DrugBank: APD791 (DB05227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for APD791
Study: NCT00445770
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg twice weekly, subcutaneous injection for 52 weeks
Study: NCT00445770
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg, twice weekly, subcutaneous injection for 52 weeks
Study: NCT00965419
Drug: Edivoxetine
Normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
Study: NCT03857542
Drug: Pilocarpine HCl Ophthalmic Solution
Normalized name: pilocarpine hydrochloride Ophthalmic Solution
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
Study: NCT04412707
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral versus central administration
Study: NCT04412707
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets
Study: NCT03044808
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03044808
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05840536
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
Study: NCT02386501
Drug: ADXS31-164
DrugBank: ADXS-31164 (DB17325)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00551603
Drug: switch (epoetinum beta, darbepoetinum)
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
Study: NCT02831933
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prodrug of the antiviral drug acyclovir
Study: NCT02831933
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
Study: NCT01831674
Drug: Metformin Hydrochloride Extended-Release Tablets USP 750
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
Study: NCT01969435
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01969435
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01969435
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01969435
Drug: Melphalan HCl (propylene glycol-free)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04751188
Drug: Bezafibrate 200 MG Oral Tablet
Normalized name: bezafibrate 200 MG Oral Tablet
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate one tablet every 12 hours for six months.
Study: NCT04751188
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At a dose of 13 to 15 mg per Kg per day.
Study: NCT02215135
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
Study: NCT04204044
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride is used in PCO
Study: NCT04204044
Drug: Myo-inositol
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo inositol used in PCO
Study: NCT01270438
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00518271
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02685228
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: decitabine 5mg/m2,d1-d5;
Study: NCT02685228
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1.0g/m2, d8,d15,d22
Study: NCT01673620
Drug: Montelukast 10 mg/loratadine 10 mg
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 10 mg/loratadine 10 mg tablet administered once daily
Study: NCT00988949
Drug: PF-04455242
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 18 mg dose of PF-04455242.
Study: NCT00988949
Drug: spiradoline
Normalized name: Spiradoline
DrugBank: Spiradoline (DB12704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
Study: NCT00988949
Drug: PF-04455242
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 30 mg oral dose of PF-04455242.
Study: NCT00949910
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
Study: NCT04397562
Drug: Levilimab
Normalized name: Levilimab
DrugBank: Levilimab (DB16387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levilimab 324 mg
Study: NCT01890408
Drug: wound infusion ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours.
Study: NCT02522325
Drug: Phendimetrazine
Normalized name: Phendimetrazine
DrugBank: Phendimetrazine (DB01579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phendimetrazine will be administered in divided doses twice daily.
Study: NCT02522325
Drug: Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine will be administered during experimental sessions.
Study: NCT01318148
Drug: caspofungin
Normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent intravenous application of caspofungin
Study: NCT04500886
Drug: rhG-CSF
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
Study: NCT01012544
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
Study: NCT03458650
Drug: LXI-15028 50mg
Normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
Study: NCT03458650
Drug: LXI-15028 100mg
Normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
Study: NCT03458650
Drug: LXI-15028 200mg
Normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
Study: NCT00388258
Drug: Alvimopan
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00856258
Drug: PF 03882845 and Placebo
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
Study: NCT00856258
Drug: PF 03882845 and Placebo
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
Study: NCT00303615
Drug: Fluoxymesterone 10 mg
Normalized name: fluoxymesterone 10 MG
DrugBank: Fluoxymesterone (DB01185)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00303615
Drug: Anastrozole 1 mg
Normalized name: anastrozole 1 MG
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005085
Drug: becatecarin
Normalized name: Becatecarin
DrugBank: Becatecarin (DB06362)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01611766
Drug: Salvage Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of postoperative chemotherapy
Study: NCT04811001
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
Study: NCT04811001
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
Study: NCT01883869
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02752724
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Study: NCT02752724
Drug: Methohexital
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Study: NCT00352313
Drug: ATN-161
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00352313
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00696436
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.
Study: NCT00696436
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.
Study: NCT00696436
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.
Study: NCT00696436
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.
Study: NCT00833807
Drug: Nab-Paclitaxel (Abraxane)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days.
Study: NCT03943446
Drug: TAK-018
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-018 immediate-release tablets.
Study: NCT01281189
Drug: Dexpramipexole
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet 150mg twice daily for up to 18 months.
Study: NCT03200093
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
Study: NCT02812719
Drug: Glycolic acid peel alone
Normalized name: orange peel extract
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals
Study: NCT02467023
Drug: Muscle Biopsy Medication: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
Study: NCT02812719
Drug: Glycolic and salicylic acid peel
Normalized name: glycol salicylate / nonivamide / salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.
Study: NCT01454479
Drug: Lapatinib and ixempra
Normalized name: IXEMPRA
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ixabepilone 40 mg/m2 Lapatinib 250 mg
Study: NCT00890383
Drug: tetrastarch (Voluven)
Normalized name: Hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goals directed volume therapy for severe trauma resuscitation
Study: NCT01313897
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
Study: NCT03652051
Drug: AZR-MD-001 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZR-MD-001 is an ophthalmic ointment
Study: NCT03652051
Drug: AZR-MD-001 High Dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 is an ophthalmic ointment
Study: NCT06377722
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
Study: NCT04235439
Drug: Gan & Lee Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
Study: NCT01823770
Drug: Rotigotine
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
Study: NCT01273493
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.